Moderna: reviews its trial programs

(CercleFinance.com) - Moderna today announced progress across its portfolio of mRNA programs presented at the company's annual R&D day.


The pioneering biotech company in the field of messenger RNA (mRNA) therapeutics and vaccines, builds on continued advances in basic and applied mRNA science, delivery technology and manufacturing, and has enabled the development of treatments and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.

The group said that its Phase 3 clinical trials in influenza and RSV are progressing rapidly towards completion, with it seeing early clinical benefits in two rare disease programs: it expects to report data from its personalised cancer vaccine trial later this year.

Bodes well... the share is up 1.5% in pre-market trading today.


Copyright (c) 2022 CercleFinance.com. All rights reserved.